NEW: Embedded cohort program license — from $45,000/yr, designed to fold into SBIR/STTR & grant budgets Learn More
For Incubators & Accelerators
The same MD + biomedical-engineer, fully-cited diligence your founders' VCs run — delivered to every company in your cohort as a per-cohort annual license that folds into your program and grant budgets.
Or email arvind@vantagebiomed.com directly
The Challenge
The gap between breakthrough science and commercial success is where most medtech innovations die.
Incubators and accelerators are evaluated on one metric: how many cohort companies raise their next round. But most programs lack the clinical and regulatory assessment infrastructure to identify which companies are investor-ready and which have structural barriers that no amount of mentorship will fix.
Vantage provides that infrastructure. Our physician-engineer team evaluates regulatory pathway viability, reimbursement feasibility, clinical adoption likelihood, and commercial readiness — the same dimensions that investors scrutinize during diligence. You get the answers before demo day, not after.
Assessment Scope
Our comprehensive assessment evaluates multiple material risk factors across all commercialization dimensions. See full methodology →
510(k), De Novo, PMA routing; predicate density; probable submission timeline and feedback risk.
CPT/HCPCS coverage path, payer policies, coding gaps, expected per-procedure economics.
KOL posture, workflow fit, evidence bar, and comparable-product adoption curves in the target setting.
Patent landscape, claim strength, third-party encumbrances, and near-term FTO risk.
Design for manufacturability, supplier concentration, quality system maturity, scale-up economics.
Domain experience, gaps in regulatory/clinical leadership, commercial plan defensibility.
Vantage assessments directly support SBIR/STTR Phase I and Phase II applications. Our regulatory pathway analysis, clinical evidence evaluation, and commercialization roadmaps strengthen the technical merit and broader impact sections that reviewers score — the same artifacts a sound program officer wants to see on the technical and commercialization side.
Know which teams are investor-ready, which need course corrections, and which have fundamental adoption problems — before they pitch.
Founder pivoted regulatory approach before filing, saving estimated 12-18 months of wasted development.
Company engaged payer strategy consultant based on our roadmap, secured CPT code pathway 6 months faster than industry average.
Founder used the Vantage Index in Series A data room; round closed in 6 weeks with clean IP landscape validation.
Your Biggest Challenges, Solved
The Vantage Index provides an objective, quantified ranking across your entire portfolio. Instead of gut-feel prioritization, you get data-driven triage. Technologies scoring 70+ are investor-ready; 50-69 need targeted development; below 50 need fundamental pivots.
Every score comes with a board-ready summary. Show stakeholders exactly where each company stands across clinical, regulatory, manufacturing, and commercial dimensions — with before-and-after comparisons that demonstrate how your program is de-risking the portfolio. Quantified progress that sponsors and LPs can actually evaluate.
The Vantage Index becomes a credibility asset. When your portfolio company walks into VC pitches with an independent, written clinical-technical assessment — risks named, remediation prioritized, and a defensible Score on the cover — it signals the kind of investor-ready preparation peer cohorts rarely show up with. The point isn’t a magic number; it’s that the hard questions are already answered before the partner asks them.
That's exactly what we provide. Our MD + BME team evaluates the same dimensions that VC investors will scrutinize — regulatory pathway, clinical adoption, manufacturing feasibility, reimbursement — so your cohort companies are prepared before they ever pitch.
Embedding Vantage into your cohort program gives you a differentiation that competing incubators don't have: every graduate leaves with a clinical-technical risk profile that VCs recognize. Your program becomes known for producing investor-ready companies — not just companies that completed a curriculum. That drives better deal flow for your next cohort.
The Vantage assessment doesn't just score — it prescribes. Each company gets a specific roadmap: this one needs a predicate strategy pivot, that one needs a reimbursement pathway before clinical evidence. Your mentors and advisors get targeted assignments instead of generic coaching. Program time goes from broad curriculum to surgical intervention.
Use Cases
Cohort-wide assessment at intake, mid-program, or pre-demo day. Identify which companies need regulatory pivots, reimbursement strategy, or clinical validation before investors ask the hard questions.
Commercial viability assessment for grant milestones. Our framework maps directly to the commercialization readiness that NIH/NSF reviewers evaluate at Phase II transition.
Portfolio-level risk triage for venture studios building multiple companies in parallel. Score each venture's clinical-technical readiness to prioritize where capital and attention go next.
Pricing for Incubators & Accelerators
Lead with a per-cohort annual license that folds into your SBIR/STTR, NIH, and state economic-development grant budgets — every founder in your cohort gets a cited, physician + engineer risk read. One-off per-company assessments remain available lower down.
Annual Cohort Program Licenses — Fundable Through Grant Budgets
One-Off Per-Company Options
A 10-company cohort screened at $5,000 each ($50,000 total) identifies the 2-3 companies with the strongest commercialization potential — saving months of mentorship resources on companies with unresolvable technical barriers.
Illustrative Scenario
Transparency note: This is an illustrative walkthrough, not a paid engagement — it shows the kind of output a cohort assessment produces. We’ll cite real client work by name when sponsors permit.
In an illustrative 10-company cohort spanning medical devices (4), digital health (3), diagnostics (2), and a combination product (1), Vantage's scoring surfaced that 6 of 10 had viable regulatory pathways but only 3 had realistic reimbursement strategies. On that basis an accelerator could restructure mentorship pairings — connecting the companies with gaps to domain-specific advisors before demo day, so scarce mentorship goes where it moves the needle.
Deliverables
Every incubator assessment delivers actionable risk evaluation for your portfolio companies. Here's what a real assessment looks like.
See a Sample Evaluation →Every assessment is delivered under our standard engagement terms, with reperformance or refund as the remedy if a deliverable does not conform to the agreed scope. Our work product reflects independent, physician-led, engineer-built diligence — not investment advice and not a guarantee of outcomes.
Cohort-anchored differentiator analysis with effect-size disclosure across 800+ outcome-labeled biomedical companies in our proprietary cohort substrate, growing with every engagement
Your Assessment Team
Led by Dr. Arvind Ravinutala (MD, practicing physician) and Aswini Ravinutala (BME, 8+ years medical device engineering, ex-Axonics/Boston Scientific). Meet the full team →
Cohort Intelligence
Screen every company at once. Bulk discounts kick in at 5+ companies — as low as $4,000/company at 20+.
Use our Deal Flow Evaluation service to assess your entire incubator cohort or portfolio at once. Submit all companies and receive ranked assessments with clinical, commercial, and technical viability scores in 24–48 hours. Quick Screen is $5,000 per company with bulk discounts (10% off 5+, 15% off 10+, 20% off 20+) — as low as $4,000 per company at 20+ companies.
Use case: At cohort intake or graduation, screen all companies to identify which ones are best positioned across clinical adoption, manufacturing excellence, and investor appeal on documented risk factors. Direct mentorship and investor connections to the strongest candidates.
The 15 most common regulatory, clinical, and commercial red flags that kill life science deals — and how to spot them before they cost you. Written by Arvind Ravinutala, MD and Aswini Ravinutala, BME.
Download the GuideNo email required. No paywall.
Bring Vantage into your program as a per-cohort annual license that folds into your grant and program budgets — every founder leaves with a cited, physician + engineer risk read VCs recognize. Prefer to start small? Screen a single company first.
Embedded cohort licenses fold into SBIR/STTR, NIH, and state economic-development grant budgets. Book a free discovery call and we'll design the license that fits your program cycle.